

Dan Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5606634/publications.pdf>

Version: 2024-02-01

60
papers

795
citations

687363

13
h-index

552781

26
g-index

68
all docs

68
docs citations

68
times ranked

1557
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrahepatic cholangiocyte regeneration from an Fgf4-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome. <i>Hepatology</i> , 2022, 75, 567-583.	7.3	12
2	Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5%. <i>European Journal of Radiology</i> , 2022, 147, 110100.	2.6	1
3	Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	8
4	Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 843376.	2.8	2
5	Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16244-e16244.	1.6	0
6	A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16261-e16261.	1.6	0
7	Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e050558.	1.9	1
8	Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification. <i>Frontiers in Oncology</i> , 2021, 11, 538328.	2.8	6
9	The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1091-1098.	2.2	0
10	Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2815-2819.	2.0	2
11	Bevacizumab Combined with S1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326.	3.7	3
12	Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials. <i>Translational Cancer Research</i> , 2021, 10, 1628-1643.	1.0	0
13	Combination of gemcitabine, nab-paclitaxel, and S-1 (GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study. <i>BMC Cancer</i> , 2021, 21, 545.	2.6	2
14	Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16213-e16213.	1.6	3
15	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2021, 19, 301.	4.4	12
16	Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. <i>Pharmacological Research</i> , 2021, 172, 105808.	7.1	20
17	Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 759652.	2.8	3
18	Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 636.	2.6	8

#	ARTICLE	IF	CITATIONS
19	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570268.	2.8	3
20	Efficacy of chemotherapy combined with toripalimab in PD-L1 ⁺ positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report. <i>Tumori</i> , 2020, 107, 030089162098079.	1.1	4
21	The association between SNPs and hepatitis B virus related acute-on-chronic liver failure. <i>Infection, Genetics and Evolution</i> , 2020, 86, 104615.	2.3	0
22	Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction. <i>Medicine (United States)</i> , 2020, 99, e19884.	1.0	4
23	Alteration of Transforming Growth Factor β 2 Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 534-542.	1.1	2
24	Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer. <i>Precision Clinical Medicine</i> , 2020, 3, 67-70.	3.3	4
25	Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 1127.	4.8	9
26	Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e033120.	1.9	3
27	Oncogene-dependent function of BRG1 in hepatocarcinogenesis. <i>Cell Death and Disease</i> , 2020, 11, 91.	6.3	23
28	An Unexpected Case Report of Adrenal Lymphangioma: Mimicking Metastatic Tumor on Imaging in a Patient With Pancreatic Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 610744.	3.5	1
29	Combined recombinant humanized anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16792-e16792.	1.6	0
30	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2020, 10, e035802.	1.9	1
31	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2020, 10, e035802.	1.9	1
32	PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 182, 110356.	5.0	5
33	Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. <i>Radiation Oncology</i> , 2019, 14, 120.	2.7	16
34	Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2019, 9, 470.	2.8	7
35	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 591-e165.	3.7	11
36	Reconstruction and Analysis of the Differentially Expressed lncRNA-miRNA-mRNA Network Based on Competitive Endogenous RNA in Hepatocellular Carcinoma. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2019, 29, 539-549.	0.9	10

#	ARTICLE	IF	CITATIONS
37	<p>Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11339-11344.	2.0	1
38	Alteration of TGF- β signaling pathway predicts worse prognosis in pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13006-e13006.	1.6	0
39	Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15606-e15606.	1.6	0
40	ETV2 mediates endothelial transdifferentiation of glioblastoma. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 4.	17.1	33
41	RhoA-estimated intra-vascular morphology switch facilitates the arrest of individual circulating tumor cells. <i>International Journal of Cancer</i> , 2018, 142, 2094-2105.	5.1	13
42	Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. <i>Medicine (United States)</i> , 2018, 97, e13113.	1.0	17
43	CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5559-5567.	2.0	14
44	Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1339-1346.	2.5	8
45	Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15565-e15565.	1.6	0
46	Both <i>de novo</i> synthesized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. <i>Liver International</i> , 2017, 37, 80-89.	3.9	60
47	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. <i>Journal of Hepatology</i> , 2017, 67, 1194-1203.	3.7	77
48	Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model. <i>Scientific Reports</i> , 2017, 7, 14372.	3.3	35
49	5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 60173-60187.	1.8	6
50	The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6581-6595.	2.0	4
51	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. <i>Gastric Cancer</i> , 2016, 19, 245-254.	5.3	7
52	Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells. <i>Tumor Biology</i> , 2016, 37, 7213-7227.	1.8	12
53	Endostatin improves cancer-associated systemic syndrome in a lung cancer model. <i>Oncology Letters</i> , 2015, 9, 2023-2030.	1.8	1
54	Bleeding after Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer. <i>Tumori</i> , 2015, 101, 46-51.	1.1	8

#	ARTICLE	IF	CITATIONS
55	A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. <i>Medical Oncology</i> , 2015, 32, 247.	2.5	4
56	Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment. <i>Oncology Reports</i> , 2015, 33, 2981-2991.	2.6	32
57	Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2014, 112, 250-255.	0.6	82
58	Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	16
59	Successful treatment of liver metastasis from solid pseudopapillary tumor of the pancreas: a. <i>Wspolczesna Onkologia</i> , 2013, 4, 400-403.	1.4	3
60	Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. <i>BMC Cancer</i> , 2009, 9, 432.	2.6	173